The Europe Melanoma Drugs market size stood at around USD 750 million in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Melanoma is a type of skin cancer, which occurs when pigment-producing cells of the skin grow uncontrollably leading to formation of unusual growth in the body or changes in existing moles. It has a tendency to metastasise which leads to poor prognosis.
In Netherlands, dermatologists warn of a ‘skin cancer epidemic’ as the number of melanoma cases keep increasing. It accounts for 6.3% of total new cancer diagnosis in Netherlands. In 2017, expenditure on skin cancer care totalled 168.6 million euros. This corresponds to 2.9% of the total expenditure on health care for new formation and 0.19% of the total expenditure on health care in the Netherlands.
The market in Netherlands is driven by the ever-increasing cases of melanoma. In the period between 1990 to 2019, the number of melanoma cases in women and men have tripled and quadrupled respectively. In 2020, around 6,800 new cases on melanoma were diagnosed in Netherlands. This is less than the number in 2019 (7,029) because of decreased diagnosis due to the COVID 19 pandemic. However, according to statistics, melanoma remains in the top 5 cancers which cause death in Netherlands.
Some other market drivers include approval and uptake of branded drugs and the development of immunotherapy and checkpoint inhibitor drugs.
Increased research and development towards melanoma treatment also drives the market.